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Abstract
Purpose: Experimental animal models of myopia demonstrate that higher mela-
tonin (Mel) and lower dopamine (DA) concentrations actively promote axial
elongation. This study explored the association between myopia and serum con-
centrations of DA and Mel in humans.
Methods: Morning serum concentrations of DA and Mel were measured by solid
phase extraction-liquid chromatography-tandem mass spectrometry from 54 par-
ticipants (age 19.1  0.81 years) in September/October 2014 (phase 1) and
March/April 2016 (phase 2). Axial length (AL), corneal radii (CR) and spherical
equivalent refraction (SER) were also recorded. Participants were defined as myo-
pic if non-cycloplegic spherical equivalent refractive error ≤0.50 DS at phase 1.
Results: Nine participants were lost to follow up. Mel concentrations were mea-
surable for all myopes (phase 1 n = 25, phase 2 n = 22) and non-myopes (phase
1 n = 29, phase 2 n = 23). SER did not change significantly between phases
(p = 0.51). DA concentrations were measurable for fewer myopes (phase 1
n = 13, phase 2 n = 12) and non-myopes (phase 1 n = 23, phase 2 n = 16).
Myopes exhibited significantly higher Mel concentrations than non-myopes at
phase 1 (Median difference: 10 pg mL1, p < 0.001) and at phase 2 (Median dif-
ference: 7.3 pg mL1, p < 0.001) and lower DA concentrations at phase 2 (Med-
ian difference: 4.7 pg mL1, p = 0.006). Mel concentrations were positively
associated with more negative SER (all r ≥ 0.53, all p < 0.001), longer AL (all
r ≥ 0.37, all p ≤ 0.008) and higher AL/CR ratio (all r ≥ 0.51, all p < 0.001).
Conclusion: This study reports for the first time in humans that myopes exhibit
higher serum Mel concentrations than non-myopes. This may indicate a role for
light exposure and circadian rhythm in the human myopic growth mechanism.
Further research should focus on younger cohorts exhibiting more dynamic myo-
pic progression and explore the profile of these neurochemicals alongside evalua-
tion of sleep patterns in myopic and non-myopic groups.
Introduction
Myopia presents an economic burden both in terms of the
cost of refractive correction and the increased risk of visual
impairment arising from associated pathology including
glaucoma1 and chorioretinal atrophy.2,3 Myopia is a grow-
ing health concern4 with global estimates indicating the
number of cases of myopia will reach 324 million by 2025
resulting in an increase in the prevalence of pathological
scleral and choroidal degenerations associated with high
myopia.3 Much attention has been directed towards under-
standing the risk factors associated with myopia and the
development of interventions to reduce the incidence and
progression of myopia in childhood.5–8 Research has
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demonstrated that many factors contribute to the onset
and progression of myopia; genetics, lifestyle and visual
environment have all been shown to have significant roles9–
11 and manipulation of the latter two factors hold promise
for reducing incidence and progression. To-date the most
promising interventions include modifying the image pro-
file projected to the peripheral retina,12,13 increasing the
amount of time a child spends outdoors,7,14,15 and applica-
tion of pharmacological agents such as adenosine antago-
nist 7-methylxanthine (7-mx)16 or the anti-cholinergic
agent atropine8. The latter has recently been shown to cause
thickening of the choroid in young children (aged 5–
10 years).17 The mechanism by which these visual, environ-
mental and pharmacological interventions influence refrac-
tive status are currently unclear.
Circadian rhythms contribute to the control of ocular
physiological process and have been demonstrated within
both mammalian and non-mammalian ocular tissue
including the cornea and retina.18,19 Circadian rhythms
have also been reported in axial length and choroidal
thickness in the human eye.20–22 Stone et al.22 propose
that disruption of retinal circadian rhythm may be a key
element promoting dysregulation of eye growth and hence
myopia. Indeed, Weiss and Schaeffel23 report that form
deprived chick eyes do not demonstrate the same circa-
dian fluctuation in axial length as control eyes; axial length
increased at a faster rate during the night than during the
day in form deprived eyes. Nickla et al24 demonstrated
that disruption of circadian rhythm in chicks, through
exposure to two hours of bright light during the night,
leads to abolition of diurnal variations in choroidal thick-
ness and axial elongation. Furthermore, Bertolet et al.25
reported that in healthy young adults, choroidal thickness
was significantly greater at 6 pm than at noon in emme-
tropes but this diurnal variation was not reported in
myopes. This relation between circadian rhythm and myo-
pia is not limited to the eye; a recent report by Ayaki
et al.26 describes poorer sleep quality in highly myopic
children and young adults when compared with less myo-
pic or emmetropic peers.
Systemic circadian rhythms are primarily regulated by
the hypothalamic suprachiasmatic nucleus in the brain
which also control the circadian release of the neurohor-
mone melatonin (Mel) and the neurotransmitter dopamine
(DA). Mel concentrations are greatest during the night and
DA concentrations are greatest during the day. The synthe-
sis of Mel primarily occurs in the pineal gland in humans27
and has also been documented in ocular cells and structures
including retinal photoreceptors in the frog eye28 and cil-
iary epithelial cells in human eyes.29 Three Mel receptors
(Mel1a, Mel1b and Mel1c) have been located throughout the
retina, the sclera and the cornea of the frog,30,31 the chor-
oid, the retina and the sclera of the chick eye32,33 and
retinal ganglion cells and inner nuclear layers of guinea pig
eyes.33
Melanopsin is a blue light-sensitive photopigment whose
synthesis is partially modulated by Mel.34 Melanopsin can
be found within intrinsic photosensitive retinal ganglion
cells within the mammalian eye.35 These intrinsically pho-
tosensitive retinal ganglion cells innervate the hypothalamic
suprachiasmatic nucleus within the brain, contributing to
the entrainment of the light mediated circadian clock (cir-
cadian photoentrainment).36 They also contribute to light
mediated responses within the eye, including the pupillary
light response, and influence the activity of dopaminergic
retinal cells.37,38 Schaeffel et al.39 explored the association
between refractive error and melanopsin signal strength in
adults aged 18–87 years. The differential in recovery time
of the pupillary response to blue and red light was used to
indicate melanopsin response but no association was found
with refractive error. No research has yet explored the asso-
ciation between Mel and refractive error in humans.
Although DA is primarily regarded as a cerebral neuro-
transmitter, it is also released from retinal type 2 amacrine
and interplexiform cells within the mammalian eye.40 Its
functions within the eye are numerous including involve-
ment in retinal light adaptive processes40,41 and retinal pig-
ment epithelium physiology.40The functions of DA are
mediated by D1 and D2 receptor families. The D1 receptor
family (D1 and D5 receptors) have been shown to be pre-
dominantly located in the retina within bipolar, horizontal,
amacrine and ganglion retinal cells in mammalian and
chick eyes.40,42 The D2 receptor family (D2, D3 and D4
receptors) have been shown to be predominantly located
within the RPE in the chick eye43,44 and, specifically, within
the photoreceptor layer in the human eye.45
Mel and DA form a mutual inhibitory relationship
whereby Mel negatively influences DA release in both neu-
ral and ocular tissue, including the retina. Previous reports
have explored the role of Mel and DA in animal models of
myopia. Lower retinal DA concentrations are reported in
experimental chick myopia.46–48 Stone et al48 demonstrate
that DA retinal synthesis is reduced in one-day old form
deprived chick eyes and the authors propose that DA may
contribute to the regulation of emmetropization and nor-
mal ocular growth. Furthermore, the enrichment of DA
concentrations using DA agonist (apomorphine) eye drops
retards the development of form deprivation myopia in
primates49 and in chicks.48 Similarly, in guinea pig eyes,
Dong et al.50 demonstrated that application of subconjunc-
tival injections of apomorphine inhibits the development
of form deprivation myopia.
Although ocular growth is believed to be locally regu-
lated,51 circulating blood concentrations of DA and Mel are
likely to influence the highly vascular ocular tissues and
hence ocular growth. This has previously been evidenced in
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chicks in which systemic administration of Mel promoted
choroidal thinning32 and in guinea pigs where the systemic
injection of a precursor of DA (levodopa) retarded the
development of form deprivation myopia.52 Ocular Mel
and systemic circulating Mel concentrations have also been
shown to be associated in the frog53 and Newt eye.54
While animal studies indicate that refractive status can
be manipulated with systemic and ocular administration of
Mel and DA there are no previous studies investigating the
association between Mel and DA with myopia in humans.
The aim of this prospective, observational study was to
explore the association between myopia and serum concen-
trations of DA and Mel in a human population for the first
time.
Materials and methods
Initial measures were completed in September/October
2014 (phase 1) and repeated 18 months later in March/
April 2016 (phase 2). This facilitated the exploration of sea-
sonal variation in Mel and DA concentrations. Participants
were aged 18–20 years at phase 1 and were recruited from
first year undergraduate students attending Ulster Univer-
sity (Coleraine campus (55°N).
Participants with a diagnosed medical condition or tak-
ing prescribed medication known to affect DA or Mel con-
centrations, such as levodopa and Mel, were excluded.
Ethical approval was granted from the Ulster University
Research Ethics Committee (REC/14/0003) and written
informed consent was obtained from all participants before
commencing the study protocol and after explanation of
the nature and possible consequences of the study.
Research adhered to the tenets of the Declaration of Hel-
sinki. All blood samples were processed and stored in
accordance with the Human Tissue Act 2004.
Autorefraction, ocular biometry and parental myopia
Non-cycloplegic autorefraction was completed using the
Shin-Nippon SRW-5000 binocular open field autorefractor
(Shin-Nippon, Tokyo, Japan) while the participant viewed
a distance target. The representative value from each eye
was determined by the instrument and the average of both
eyes used in analysis. Participants were defined as myopic if
the spherical equivalent refraction (SER) equated to less
than or the equivalent of 0.50 dioptre sphere (DS).55
Axial length and corneal radii (CR) were measured using
the IOL Master (https://www.zeiss.com/meditec/int/produc
ts/ophthalmology-optometry/cataract/diagnostics/optical-
biometry/iolmaster-500.html). A total of five AL measures
with a signal-to-noise ratio of greater than two were mea-
sured from each eye. The average of both eyes was used in
analysis. A total of three CR measures were also recorded
from each eye and the average of both eyes included in
analysis. The AL to CR ratio (AL/CR) was determined from
these measures and an average value was derived from both
eyes for each participant.
Data on parental myopia was determined from a vali-
dated refractive status questionnaire56 and categorised as
either ‘0 parents myopic’, ‘1 parent myopic’ or ‘both par-
ents myopic’.
Blood collection
Circulating serum concentrations of Mel and DA were
determined from fasting blood samples. Participants were
required to fast from 10 pm the previous evening. A 4 mL
serum blood sample (https://shop.gbo.com/en/row/produc
ts/preanalytics/venous-blood-collection/vacuette-tube/se
rum/) was collected from the antecubital vein between
8.30 am and 10 am. Sampling times were restricted in this
way to reduce inter and intra-participant variation in Mel
and DA arising from circadian rhythm and daylight expo-
sure.57
Serum samples were centrifuged at 2200 g for 15 min at
4°C (http://www.mseuk.co.uk/Products/Centrifuges/Refrig
erated/Harrier_18_80R/Default.aspx) within two hours of
collection and 1000 lL of serum was isolated from the cen-
trifuged sample. The analysis of DA from phase 1 serum
samples indicated that this analyte was not as readily
detected as Mel. Therefore, serum samples from phase 2
intended for DA analysis were preserved in a final concen-
tration of 0.1% ascorbic acid solution 0.1 M hydrochloric
acid to prevent degradation of this analyte. All samples
were stored at 80°C prior to analysis.
DA and Mel analysis
DA and Mel were quantified using liquid chromatography
followed by on-line solid phase extraction and tandem
mass spectrometry analysis (LC-On-Line SPE-MS/MS).
Quantification was performed on an API 4000 (AB Sciex,
Warrington, UK) coupled to a Shimadzu LC system con-
sisting of a controller (CBM-2A), auto sampler (SIL-
20ACxr), LC pumps (20AD xr,) loading pump (20ADsp)
and column oven (CTO-20A) (Shimadzu, Kyoto, Japan). It
was operated using Analyst software (version 1.6.1, AB
Sciex, Warrington, UK). The limit of quantitation (LOQ)
for Mel was 2 pg mL1 (signal/noise (S/N) = 32.1, Coeffi-
cient of Variation (CV) (n = 3) = 3.45%) and the LOQ for
DA was 10 9 103 pg mL1 (S/N = 23.3, CV,
(n = 3) = 4.6%).
The values for intra- and inter- assay precision and accu-
racy were acceptable (<20% Relative Standard Deviation
(RSD) for precision and 20% accuracy) at the LOQ of
2 pg mL1 for Mel and LOQ of 10 9 103 pg mL1 for
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DA. Acceptable reproducibility for DA and Mel measures
upon repeat injections was demonstrated with a RSD of
2.2% for DA and 4% for Mel in serum samples.58
Statistical methods: sample size
Owing to the novel nature of the study, sample size calcula-
tions were applied retrospectively to determine statistical
power.
Statistical methods: analysis
All statistical tests were performed using Stata 13.1 (Stata-
Corp Texas, USA) using a statistical significance level of 5%
throughout (p < 0.05).
All measures of Mel were normally distributed as indi-
cated by the Skewness and Kurtosis test for normality (all
p ≥ 0.066). Phase 2 measures of DA were also normally dis-
tributed (p = 0.18). As phase 1 measures of DA were not
normally distributed (p = 0.041), data were squared to fol-
low a normal distribution as indicated by the Stata Ladder
of powers test.59 For comparison purposes, graphical data
presented pertain to raw data.
DA and Mel concentrations may be subject to seasonal
variation60,61 therefore, data from phase 1 (end of summer)
and phase 2 (end of winter) were analysed separately.
Spearman’s correlation was used to assess the correlation
between DA, Mel and continuous ocular biometric vari-
ables including; SER, AL, CR and AL/CR. Fisher’s exact test
was used to assess the relationship between parental myopia
and the presence of myopia.
Multiple imputation by chained equations was used to
account for missing data arising from participant drop
outs.62 A repeated logistic regression model including the
imputed data was used to assess the relationship between
the presence of myopia (yes/no) and DA and Mel concen-
trations. A linear regression model including the imputed
data was used to assess the relationship between DA, Mel
and change in SER, AL, CR and AL/CR over the 18-month
study period.
DA and Mel were included as predictors. A total of 50
imputed datasets were generated for DA and 15 for Mel.
Active imputation was used to address missing AL/CR
values.
Results
Participant characteristics
A total of 83% of participants with measures at phase 1
(n = 54) also had available data at phase 2 (n = 45). Of the
nine participants who dropped out; five participants had
left the University, three participants were non-contactable
and one participant did not want to have a repeat blood
sample taken. The baseline characteristics of those who
dropped out did not significantly differ by SER (d.f. = 52,
p = 0.47), parental myopia (v2 = 3.1, p = 0.079) or by
gender (v2 = 0.58, p = 0.45) from those who did not drop
out. Myopes (SER ≤ 0.50 DS) and non-myopes
(SER > 0.50 DS) were classified from refractive data col-
lected at phase 1. Table 1 summarises the available refrac-
tive and ocular biometric data at each phase for myopes
and non-myopes.
Spherical equivalent refraction was relatively stable over
the study period in both the myopic (mean change SER:
0.22  0.27DS) and the non-myopic (mean change SER:
0.01  0.43DS) groups and change in SER was not statisti-
cally significant in either group (all p ≥ 0.079). Participants
who were classified as non-myopic or myopic at phase 1
remained within their respective refractive status categories
throughout the study period.
DA and Mel: characteristics
Serum samples were collected from each participant at
approximately the same time (mean difference between
phase 1 and phase 2 = 30.3 min (standard deviation
(S.D.): 8.2) min). Mel was detectable within all serum sam-
ples analysed at phase 1 and phase 2. Of the 54 samples
analysed at phase 1, DA concentrations were detectable for
36 participants (66%). Of the 45 samples at phase 2 con-
taining the ascorbic acid stabiliser, DA concentrations were
detectable for 28 participants (62%). There was no statisti-
cally significant seasonal variation in Mel (p = 0.75) or DA
(p = 0.31). DA was inversely correlated with Mel at phase 1
Table 1. Summary statistics describing refractive and ocular biometric
values of myopes and non-myopes at each phase
Average right
and left eye
(Mean (S.D.))
Myopes
(n = 25)
Non-myopes
n = 29 d.f.a p
Phase 1
SER (DS) 2.37  1.27 +0.62  0.89 52 <0.001
AL (mm) 24.7  0.90 23.3  0.80 52 <0.001
CR (mm) 7.8  0.26 7.9  0.28 52 0.29
AL/CR 3.2  0.09 2.9  0.09 52 <0.001
Myopes
(n = 22)
Non-myopes
(n = 23)
Phase 2
SER (DS) 2.34  1.12 +0.78  1.16 41 <0.001
AL (mm) 24.7  0.76 23.4  0.81 41 <0.001
CR (mm) 7.8  0.24 8.0  0.26 41 0.036
AL/CR 3.2  0.09 2.9  0.08 41 <0.001
SER, Spherical equivalent refraction; AL, Axial length; CR, Corneal cur-
vature; AL/CR, Axial length to corneal radii ratio.
aIndependent samples t-test.
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(q = 0.72, p < 0.001) and at phase 2 (q = 0.49,
p = 0.009).
DA, Mel and myopia (SER)
Parental myopia was significantly associated with a more
negative SER (F(2,45) = 3.56, p = 0.037) but it was not
associated with the presence of myopia (p = 0.25). There-
fore, parental myopia was only accounted for in subsequent
analysis of continuous refractive data.
When considered as a group and compared with non-
myopes, myopes exhibited significantly higher Mel concen-
trations than non-myopes at phase 1 and at phase 2
(Table 2 and Figure 1). This association was also significant
after accounting for missing data in the repeated logistic
regression model (OR = 1.1, 95% CI = 1.0–1.1,
p = 0.031). Although myopes also exhibited significantly
lower DA concentrations than non-myopes at phase 2 this
association was not significant at phase 1 (Table 2 and
Figure 1) nor when missing data in the repeated logistic
regression model were accounted for (OR = 1.0, 95%
CI = 1.0–1.0, p = 0.39).
Spherical equivalent refraction was negatively associated
with Mel at phase 1 (q = 0.53, p < 0.001) and at phase 2
(q = 0.61, p < 0.001) and this remained significant after
controlling for parental myopia (all p ≤ 0.001) (Figure 2).
DA was not associated with SER at phase 1 (q = 0.16,
p = 0.36). Although DA was positively associated with SER
at phase 2 (q = 0.44, p = 0.028) following univariate analy-
ses (Figure 2), this association did not remain significant
after accounting for parental myopia in multivariate analy-
ses (p = 0.16).
DA, Mel and ocular biometry
The association between DA, Mel and ocular biometry is
summarised in Table 3. Mel was positively associated with
a longer AL and higher AL/CR at phase 1 and phase 2
(Figure 3) but there was no association between Mel and
CR at either phase. DA was not significantly associated with
any of these ocular measures.
DA, Mel and changes in refraction and ocular biometry
There was no significant seasonal variation in Mel concen-
trations. Mel concentrations were not associated with
change in SER, AL or AL/CR between phase 1 and phase 2
amongst myopes (all p ≥ 0.47) or non-myopes (all
p ≥ 0.11).
Serum DA concentrations were also not significantly
associated with change in SER, AL or AL/CR between phase
1 and phase 2 amongst myopes (all p ≥ 0.092) or non-
myopes (all p ≥ 0.10).
Discussion
The present study describes a positive association
between the magnitude of myopia and morning serum
concentrations of Mel. Myopes demonstrated a median
Mel concentration that was up to three-times greater
than the median Mel concentration observed in the
non-myopic group. The association found between Mel
and myopic refractive error is further supported by posi-
tive associations between Mel, AL and AL/CR; most
strongly between Mel and AL/CR. Morning serum con-
centrations of DA were not significantly different
between myopes and non-myopes. While our results
show an association between refractive status and serum
Mel, our data cannot be used to indicate a causal rela-
tionship. Our findings align with animal models of
experimentally induced myopia in which systemic and
ocular application of Mel has been shown to impact on
refractive status and ocular shape32 and suggest that Mel
may influence human refractive error and ocular
shape.32,49,50,52,63 Further research is required to deter-
mine the nature of this influence.
Table 2. Summary statistics indicating that myopes exhibited higher melatonin (Mel) concentrations than non-myopes at each phase and lower
dopamine (DA) concentrations than non-myopes at phase 2
Phase
Mel (pg mL1)
(Median(Interquartile range))
DA(pg mL1)
(Median(Interquartile range))
Myopes Non-myopes d.f.a p Myopes Non-myopes d.f.a p
1 15.5 (11.9–19.9)
n = 25
5.5 (3.7–7.4)
n = 29
52 <0.001 12.1 9 103
(11.0 9 103–14.4 9 103)
n = 13
16 9 103
(13.0 9 103–20.6 9 103)
n = 23
34 0.085
2 14.2 (10.1–16.6)
n = 22
6.9 (4.1–9.1)
n = 23
48 <0.001 13.1 9 103
(11.8 9 103–15.3 9 103)
n = 12
17.8 9 103
(13.4 9 103–21.3 9 103)
n = 16
26 0.006
aIndependent samples t-test.
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It is known that circulating concentrations of Mel are
higher in younger individuals64 and that myopia generally
emerges in the pre-teenage years and exhibits more active
progression with earlier onset.65 It would be valuable to
investigate serum concentrations of DA and Mel in younger
participants undergoing more dynamic refractive change to
ascertain whether these neurochemicals are linked to
refractive status in incipient myopes and possibly predictive
for refractive change and ocular biometric growth.
The finding that morning serum concentrations of Mel
in adult myopes are significantly higher than in non-myo-
pic individuals may also be important in the context of
possible treatments or preventative regimes for human
myopia, if these findings are indeed replicated in younger
individuals. Spending more time outdoors7,14 has been
shown to protect against myopia and myopic progression
in childhood and this activity may have its therapeutic
effect, at least in part, through strengthening of circadian
rhythms. There is emerging evidence that the human myo-
pic eye has atypical circadian rhythms25 and this feature of
myopia warrants further investigation in the context of
understanding the role of circadian rhythms and refractive
development.
Strengths and limitations
Mel is more efficiently ionised and therefore more sensi-
tively detected using the LC-On-Line SPE-MS/MS method
than DA. The lower success rates for measuring DA in
serum samples resulted in the study being under-powered
for exploring differences between the myopic and non-
myopic groups as indicated by retrospective sample size
calculations (power of 90%, significance 5%) using the out-
comes from the current study and when using data from
Figure 1. Box plots illustrating significantly higher Mel concentrations in myopes than non-myopes at both phases (phase 1: d.f. = 52, <0.001, P2:
d.f. = 43, p < 0.001) and significantly lower DA concentrations than non-myopes at phase 2 only (phase 1: d.f. = 34, p = 0.085, P2: d.f. = 26,
p = 0.006). Individual points indicate outliers. Phase 1: (Median (Interquartile range)): Mel: Myopes:15.5 pg mL1 (11.9–19.9 pg mL1) Non-
myopes:5.5 pg mL1 (3.7–7.4 pg mL1). DA: Myopes: 12.1 9 103 (11.0 9 103–14.4 9 103) Non-myopes: 16 9 103 (13.0 9 103–20.6 9 103).
Phase 2: (Median (Interquartile range)): Mel: Myopes:14.2 pg mL1 (10.1–16.6 pg mL1) Non-myopes:6.9 pg mL1 (4.1–9.1 pg mL1). DA:
Myopes: 13.1 9 103 pg mL1 (11.8 9 103–15.3 9 103 pg mL1) Non-myopes: 17.8 9 103 pg mL1 (13.4 9 103–21.3 9 103 pg mL1). [Colour
figure can be viewed at wileyonlinelibrary.com]
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previous inter-group comparisons of DA serum concentra-
tions.66 However, circulating serum concentrations of DA
and Mel are known to be inversely and strongly related67
and this was borne out in the present results where data for
both neurochemicals were available from single individuals;
where Mel concentrations were relatively high, DA concen-
trations were relatively low. Further work quantifying DA
concentrations from blood samples taken during the mid-
dle of the day, when DA concentrations are known to be at
their peak,40,68 rather than early in the morning, may be
more successful in quantifying DA concentrations and
hence yield larger data sets with which to compare refrac-
tive groups.
Fasting blood samples were taken between 8.30 and
10.00 am to reduce inter- and intra-participant variation in
the diurnally phasic neurochemicals under investigation.
However, no information on sleep patterns, time of wak-
ing, extent of exposure to daylight prior to blood sampling
Figure 2. Scatter graphs illustrating the association between Mel, DA and SER. Phase 1: Mel: q = 0.53, p < 0.001, R2 = 0.27. DA: q = 0.16,
p = 0.36, R2 = 0.004. Spearman’s corr. Phase 2: Mel: q = 0.61, p < 0.001, R2 = 0.34. DA: q = 0.44, p = 0.028, R2 = 0.17. Spearman’s corr. [Col-
our figure can be viewed at wileyonlinelibrary.com]
Table 3. Table summarising the association between dopamine (DA), melatonin (Mel) and ocular biometric measures at each phase. Mel was posi-
tively associated with axial length (AL) and axial length to corneal radii ratio (AL/CR) (all p ≤ 0.008) but not with corneal curvature (all p ≥ 0.059)
Mel DA
Phase 1 Phase 2 Phase 1 Phase 2
r p r p r p r p
ALa 0.37 0.008 0.52 <0.001 0.21 0.22 0.24 0.26
CRa 0.05 0.73 0.28 0.059 0.19 0.28 0.07 0.74
AL/CRa 0.51 <0.001 0.71 <0.001 0.10 0.56 0.38 0.054
aSpearman’s Correlation.
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or menstrual cycle was obtained from participants. These
are factors which have previously been shown to influence
Mel status. However, the lack of control of these factors
applies equally to the myopic and non-myopic participants
and is unlikely to undermine the almost three-fold average
difference between the myopic and non-myopic partici-
pants. Additionally, while previous research has identified
that night-time measures of Mel are influenced by season
in Finland69 where the variation in day length varies from
five hours in the winter to 22 h in the summer, our data
were collected in the morning and at a latitude which expe-
riences less extreme variation in day length.70 This may
explain the lack of seasonal variation in Mel found in the
present study, consistent with data collected at similar lati-
tude in Germany.71 Seasonal variation in Mel may be more
strongly associated with more northerly latitudes and
night-time measurement protocols. The menstrual cycle
has been reported to influence night-time measures of Mel
and this factor should be considered in further work
involving night-time samples.69
Differences in sleep patterns between myopes and non-
myopes may have contributed to the difference in Mel
serum concentrations reported in the present study. Sleep
quality was recently shown to be reduced in highly myo-
pic children26 with parents reporting that such children
had a shorter sleep duration and a later bedtime. Further-
more, in young adults 12–19 years of age,72 the risk of
myopia showed a moderate decrease with every one hour
increase in sleep. It would be valuable in future studies
to evaluate sleep quality in association with Mel and DA
serum levels.
Traditionally, myopes and non-myopes have often been
purported to have differing personality types.73 These per-
sonality traits could influence Mel levels in the two groups
under test and no evaluation of personality type was under-
taken in the present study. While more recent reports fail
to provide robust evidence for personality differences in
myopic vs non-myopic individuals,74 it may be valuable in
future studies to consider personality traits in conjunction
with biometric data and sleep characteristics.
Figure 3. Scatter graphs illustrating a positive association between Mel, AL and AL/CR. Phase 1: AL: q = 0.37, p = 0.008, R2 = 0.16. AL/CR:
q = 0.51, p < 0.001, R2 = 25; Spearman’s corr. Phase 2: AL: q = 0.52, p < 0.001, R2 = 0.22. AL/CR: q = 0.71, p < 0.001, R2 = 44; Spearman’s corr.
[Colour figure can be viewed at wileyonlinelibrary.com]
© 2017 The Authors. Ophthalmic and Physiological Optics published by John Wiley & Sons Ltd on behalf of College of Optometrists
Ophthalmic & Physiological Optics 37 (2017) 557–567
564
Dopamine, melatonin and myopia S Kearney et al.
Refractive error was determined using non-cycloplegic
autorefraction. In order to minimise the effects of proximal
accommodation and to promote a relaxed accommodative
state, a binocular open field autorefractor with a fixation
target positioned at 6 m was employed. The measurement
of refractive error using the Shin-Nippon open field autore-
fractor has been reported to be within 0.50 DS of the sub-
jective refraction measured in a cohort of a similar age.75
The significant association between morning Mel and
refractive and ocular biometric measures should be consid-
ered in the context of the R-squared values (25–44%)
which indicate that Mel may be associated with a moderate
amount of the variation in these measures. It is widely held
that there are multiple factors influencing refractive devel-
opment so these moderate R-squared values are not sur-
prising.
Conclusion
The results of the present study demonstrate that higher
serum concentrations of Mel, measured in the morning,
are associated with myopia in young adults. In the context
of experimental models of animal myopia and refractive
manipulation, and of human intervention studies evaluat-
ing treatments to retard the onset and progress of myopia,
these results provide a valuable platform for future research
into the role of neurochemicals and biological rhythms in
the development and control of refractive error.
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